Endothelin A Receptor (ETA): A Central Regulator in Cardiovascular Signaling
Exploring the molecular mechanisms and therapeutic implications of ETA in cardiovascular health.
The endothelin A receptor (ETA) is a G protein–coupled receptor (GPCR) that plays a critical role in cardiovascular physiology and pathology. ETA is predominantly expressed in vascular smooth muscle cells and cardiomyocytes, where it mediates the biological effects of endothelin-1 (ET-1), one of the most potent endogenous vasoconstrictor peptides.
Figure 1: Mechanism of ET-1/ETA signaling in vascular cells.
I. Molecular Characteristics
ETA belongs to the class A GPCR family. Its expression is highly localized to ensure targeted cardiovascular response:
Vascular Smooth Muscle: Regulates tone.
Cardiac Myocytes: Influences contractility.
Fibroblasts: Manages structural integrity.
II. Signal Transduction
Binding of ET-1 triggers the Gq/G11 pathway, activating PLC and generating key second messengers:
IP3: Induces Ca2+ release (Contraction).
DAG: Activates Protein Kinase C (PKC).
III. Cardiovascular Remodeling
Beyond immediate vasoconstriction, ETA signaling activates mitogen-activated protein kinase (MAPK) cascades, leading to chronic structural changes:
🧬
Proliferation Smooth Muscle Cells
🫀
Hypertrophy Cardiomyocytes
🕸️
Fibrosis Matrix Deposition
IV. Pathophysiological Implications
Condition
ETA Role
Hypertension
Increased peripheral vascular resistance.
Heart Failure
Promotion of myocardial remodeling and stiffness.
Atherosclerosis
Vascular wall thickening and inflammation.
V. Therapeutic Significance
Selective ETA antagonists are vital pharmacological tools. They are currently utilized in clinical settings—most notably for Pulmonary Arterial Hypertension (PAH)—to reduce vascular resistance and halt pathological tissue remodeling.
By teamBiofargo
BIOFARGO TEAM
Related Posts
Why Do Proteins Stick to Plastic Tubes? The Science Behind Low-Protein-Binding Microcentrifuge Tubes
BIOFARGO TEAM
